Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis

Nupura S. Bhise, Ron B. Shmueli, Joel C. Sunshine, Stephany Y. Tzeng, Jordan J. Green

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction: Angiogenesis is essential to human biology and of great clinical significance. Excessive or reduced angiogenesis can result in, or exacerbate, several disease states, including tumor formation, exudative age-related macular degeneration (AMD) and ischemia. Innovative drug delivery systems can increase the effectiveness of therapies used to treat angiogenesis-related diseases. Areas covered: This paper reviews the basic biology of angiogenesis, including current knowledge about its disruption in diseases, with the focus on cancer and AMD. Anti- and proangiogenic drugs available for clinical use or in development are also discussed, as well as experimental drug delivery systems that can potentially improve these therapies to enhance or reduce angiogenesis in a more controlled manner. Expert opinion: Laboratory and clinical results have shown pro- or antiangiogenic drug delivery strategies to be effective in drastically slowing disease progression. Further research in this area will increase the efficacy, specificity and duration of these therapies. Future directions with composite drug delivery systems may make possible targeting of multiple factors for synergistic effects.

Original languageEnglish (US)
Pages (from-to)485-504
Number of pages20
JournalExpert Opinion on Drug Delivery
Volume8
Issue number4
DOIs
StatePublished - Apr 2011

Keywords

  • Age-related macular degeneration
  • angiogenesis
  • antiangiogenesis
  • biomaterials
  • cancer
  • drug delivery
  • ischemia
  • nanoparticle

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis'. Together they form a unique fingerprint.

Cite this